Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
Top Cited Papers
- 27 March 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 123 (13), 2062-2065
- https://doi.org/10.1182/blood-2013-10-535443
Abstract
Key Points: Programmed death ligands 1 and 2 are rearranged at a frequency of 20% in PMBCL.Keywords
This publication has 26 references indexed in Scilit:
- Genome‐wide identification of genes with amplification and/or fusion in small cell lung cancerGenes, Chromosomes and Cancer, 2013
- Transcriptome-wide miR-155 Binding Map Reveals Widespread Noncanonical MicroRNA TargetingMolecular Cell, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- Cooperative Epigenetic Modulation by Cancer Amplicon GenesCancer Cell, 2010
- Origin of Chromosomal Translocations in Lymphoid CancerCell, 2010
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2Proceedings of the National Academy of Sciences of the United States of America, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985